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Purpose/Objective: Computerized Axial Tomography (CAT) 
scan assistance during planning Interstitial Brachytherapy 
(ISBT) with Oncentra based Inverse Planning and Simulated 
Annealing (IPSA) is used in different Institutes. ISBT has 
become an integral part for treatment of gynaecologic 
malignancies. This is an attempt to present the dose schedule 
used and analyse the outcome and radiation morbidity 
encountered.  
Materials and Methods: An institutional prospective 
analytical study since May, 2012 to May, 2014 was 
undertaken. A total of 50 cases of FIGO stage IIB to IIIB 
including 25 post operative cases of Ca. Cervix (42 Ca. Cervix 
and 8 Ca.Vagina) with 100 ISBT sessions using Martinez 
Universal Perineal Template (MUPIT) were done. Analysis was 
done in the month of Sept, 2014. All the patients underwent 
whole pelvis External Beam Radiation Therapy (EBRT) 4500 
cGy in 25 Fractions, followed by midline shielding till total 
dose of 5040 cGy in 28 fractions @ 180 cGy per fraction, 5 
days a week, with weekly Cisplatin 40 mg/m2 prior to ISBT. A 
gap of 7 to10 days was allowed after completion of EBRT 
before attempting ISBT. The anatomical relations with 
Uterus, Bladder, Rectum and Intestines were noted from pre 
implant CT Scan of the pelvis. Gap of 7-10 days between ISBT 
applications was allowed and dose ranged from 800-950 cGy 
per session. The dose to CTV, Urinary Bladder and Rectum is 
reviewed, with importance to Biological Equivalent Dose 
(BED). RTOG/ECOG criteria were used to analyse vaginal 
mucosal / bowel/ bladder early and late radiation morbidity. 
Results: There was only one case of hematuria following 
implant removal, and one case of rectal wall perforation was 
noted during the procedure. The mean dose to CTV D90 is 
8.74Gy and 0.1cc, 1cc, 2cc of Bladder and Rectum were 
8.01Gy, 6.75Gy, 6.29Gy and 7.36Gy, 6.49Gy, 6.02Gy 
respectably. The BED 8.74Gy for tumour is 85.8Gy (EBRT + 2 
sessions of IBT) with homogeneity index of. With median 
follow up of 16 months (range 4 -24 months) 3 patients had 
grade 3 vaginal mucosal toxicity, 5 patients had grade 3 
toxicity of bladder and no grade 3/4 rectal toxicity noted.  
Conclusions: The procedure is well tolerated by the patients. 
There were no immediate post procedure complications. 
Total duration of the process from spinal anaesthesia to 
removal of template is within 3 hours. This study present the 
dose schedules and fractionation which has less patient 
distress for lying in bed with the perineal template 
continuously for two to three days with comparable few 
toxicity levels. 
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Purpose/Objective: To present our first clinical experiences 
with combined intracavitary/interstitial (IC/IS) pulsed- dose-
rate brachytherapy (PDR-BT) for locally advanced cervical 
cancer using same-day MRI preplanning. 
Materials and Methods: Ten patients (FIGO IIB-IIIB) were 
treated with plastic tandem-ring (T-R, Varian) applicator 
using a custom made needle cap. For all patients treatment 
was started with pelvic±paraaortic IMRT (50.4 Gy ± 58.8 Gy 
simultaneously integrated boost to positive lymph nodes) 
with concurrent cisplatin. BT was performed on the 6th-7th 
week of the treatment. Two BT implants (BT1, BT2) followed 
by 3D SPACE MRIs with the T-R applicator in situ were 
performed in the same day in epidural anesthesia. The BT1 
was used for trajectory planning of IS needles while BT2 
comprised 35 Gy of PDR BT in 50 pulses with the implanted 
needles. Patients were re-planned without needles 
(optimized IC plan: oIC) as well. The optimization was 
stopped when the same D2cc dose parameters for OARs were 
achieved as with IC/IS approach. Dose parameters were 
compared by Wilcoxon signed-rank test. 
Results: The number of implanted IS needles was 4±1 
(Mean±SD). The depth of insertion was 25±15 mm. The 
majority (80%) of the needles was inserted in the postero-
lateral positions of the ring. The mean D90 and D98 for HR-
CTV was 90±6.2 Gy and 81.4±6.2 Gy, while for D90 IR-CTV 
was 69.5±2.9 Gy, respectively. The mean D2cc for OARs were 
the followings: bladder: 77±3 Gy, rectum: 64±3.4 Gy, 
sigmoid: 61.3±4.5 Gy and intestine: 63.8±6.4 Gy. Optimized 
IC plan significantly decreased D90 (82.5 vs. 90 Gy, p= 0.03) 
and D98 (73.9 vs. 81.4 Gy, p=0.01) for HR CTV compared to 
IC/IS at the same D2cc parameters for OARs. No serious 
perioperative complications were observed.  
Conclusions: Combined IC/IS BT based on same-day 3D MRI 
trajectory pre-planning seems to be clinically feasible 
resulting in accurate needle placement with superior 
dosimetric results compared to optimized IC plan.  
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Purpose/Objective: With about 500 000 new cases every 
year, cervical cancer is the fourth most common cancer 
affecting women worldwide, and still more than half of 
women die from the disease. There were 2783 new cases in 
Poland in 2012. Tumor volume and nodal involvement are 
prognostic of worse outcome. The purpose of this study was 
to characterize the parameters of the tumor of cervical 
cancer obtained from FDG-PET/CT and FLT-PET/CT imaging 
before radiotherapy treatment planning and to assess their 
influence on treatment decision. 
Materials and Methods: 28 patients with histological 
confirmed cervical cancer (27 planoepitheliale cancer, 1 
clarocellulare, 2pts with G1, 13pts G2, 3pts G3, 10pts G is 
not known) with FIGO stage II (12pts) and FIGO III (16pts) 
were enrolled in this study. The mean age was 52 +/-12 (SD) 
years. Routinely the patients have undergone blood analysis 
(hemoglobin and white blood cells level ) and vaginal 
bacteriology before treatment. They were examined with FLT 
PET and FDG PET.in years 2012-2014 with Gemini TF PET/CT 
scanner (Philips). PET scans were acquired on separate days 
(within one week) 60min after IV injection of 300MBq of 18F-
FDG (F-con) and 300MBq of 18F-FLT (Iason). The same scan 
protocol and reconstruction algorithms were used for both 
scans. Based on MRI calculations and phantom studies a 43% 
threshold cut-off value was selected for metabolic GTV 
delineation and volume calculation. Metabolic parameters of 
the tumor, tumor volume and clinical parameters were 
assessed on every scan separately. Data were statistical 
analyzed using p<0.05. 
Results: In all patients both tracers showed increased uptake 
in the primary tumor. The SUVmax and SUVmean were in 
general lower for FLT-GTV than FDG-GTV (7,3±2,18 vs 
12,3±4,2; p<0.001 and 4,11±1,39 vs 6,9±2,39; p<0.001). 
However, in three patients SUV values for FLT-GTV were 
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higher than for FDG-GTV. There was no significant 
differences in the volumes calculated from FLT-GTV and FDG-
GTV (45,38±47,48 vs 47,67±36,44; p=0,236).  
There was correlation between FLT volume vs FDG volume 
(R=0,7, p<0,001) and there was weak correlation between 
FDG SUVmax and level of hemoglobin (R=0,397, p=0,03). 
Analysis of other clinical and metabolic parameters were not 
significant. There were no differences observed in clinical 
and metabolic parameters in patients with lymph node 
involvement or with FIGO III. Clinical Target Volume always 
enclosed both FLT and FDG PET GTV volume. 
Conclusions: In this sample size study FLT-GTV shows the 
same volumes but lower SUVmax of thimidine within tumor 
mass as compared to glucose metabolism providing similar 
CTV for radiation therapy. There was no difference between 
tumor tracer uptake in patients with local disease and with 
lymph nodes involvement. FLT imaging may have additional 
potential role in the evaluation of tumor response to therapy 
as it shows proliferation processes.  
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Purpose/Objective: A CCD-based EPID using new crystal-
assembly X-ray (CAX) converters is investigated for 
radiotherapy dosimetry. The proposed EPID design consists in 
replacing the common phosphor X-ray converters of current 
CCD-based EPIDs with high-stopping-power CAX converters. A 
Test Imaging Device (TID), consisting of a 30-mm-thick CAX 
converter made of Bismuth Germanate (BGO), coupled to a 
highly sensitive CCD camera, was used to evaluate the 
accessible imaging and dosimetric performance of the 
proposed design. The system response to dose and its 
dependence on photon beam energy were investigated. The 
effects of ghosting, dose rate, field size and phantom 
thickness were evaluated as well. The same measurements 
were also performed with our clinically used aSi-EPID so that 
comparisons of performance could be directly inferred. 
Materials and Methods: All measurements were performed 
on an Elekta linear accelerator; model Precise. The aSi-EPID 
was an Elekta iViewGT. A calibrated 0.3 cm3 thimble-type 
PTW ionization chamber and a Wellhofer electrometer were 
used for the dose measurements. 
The test Imaging Device includes a highly sensitive, low-
noise, thermoelectrically cooled, 16-bit CCD camera 
equipped with a photographic lens and a mirror used to place 
the CCD camera out of the direct X-ray beam. The 
scintillator, used to convert the X-ray image into visible light, 
was a 30-mm-thick, 165 x 165 mm2 dimension, crystal-
assembly X-ray converter made of two BGO crystal plates and 
manufactured by Saint-Gobain Crystals. The CCD camera was 
manufactured by Princeton Instruments (Trenton, New 
Jersey, USA), model PIXIS 2048B. The CCD sensor, 27.6 x 27.6 
mm2 in dimension, is made of 2048 x 2048, 13.5 µm square 
pixels.  
Results: The TID displayed no detectable ghosting or 
sensitivity to dose rate. Its response to MU exposure was 
found to be linear within about ± 1%. The level of glare 
induced in the TID and the aSi-EPID were equivalent. The TID 
resolution was higher than that of the aSi-EPID on the axis, 
but was found to decrease with off-axis distance. Finally, the 
image quality, assessed on the basis of signal-to noise ratio in 
low dose radiographs of the larynx of a patient, was higher 
for the TID. 
Conclusions: The imaging performance accessible with the 
crystal-assembly X-ray converter proved to be satisfying and 
its dosimetric capability was found to be superior to that of 
the current aSi-EPID. The proposed design should be further 
investigated with a fully representative prototype, i.e. a 
larger-dimension CAX converter installed in a modern CCD-
based EPID in place of the metal/phosphor converter. Either 
BGO or LYSO scintillating crystal could be used to build the 
CAX converter: it may actually be useful to evaluate both 
configurations in order to identify the best suited crystal for 
clinical use.  
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Purpose/Objective: To prove the feasibility of a new 
ionization chamber technology with high spatial resolution 
for patient plan quality assurance in complex MV X-ray 
radiotherapy techniques such as IMRT and VMAT. 
Materials and Methods: The prototype under test is a linear 
array of air vented ionization chambers developed by IBA 
Dosimetry GmbH, consisting of 80 pixels with 3.5 mm spatial 
resolution and 4 mm3 sensitive volume. The detector was 
tested in a plastic phantom, performing a comparative 
clinical evaluation of treatment plans for a variety of clinical 
localizations and techniques. Treatment plans were delivered 
with two different accelerators: a Varian Trilogy (Klinikum 
rechts der Isar, Dept. of Radiation Oncology, Munich) and a 
Varian True Beam (UCSF, Dept. of Radiation Oncology, San 
Francisco) both equipped with a HD120 MLC. The 
characterization was performed for VMAT, IMRT and SBRT 
treatment plans with different beam qualities (6 MV and 15 
MV) and dose rates up to 1000 MU/min. A CT scan of the 
detector in the phantom was acquired and imported in the 
Varian Eclipse TPS in order to compare the planned dose 
distribution with the measured one. Other reference 
detectors used for comparison were radiochromic films (RCF) 
and a commercial array based on diode technology. 
Results: The ionization chamber linear array was found to be 
in very good agreement with the reference detectors for all 
different clinical evaluations. Due to the 3.5 mm spatial 
resolution, even dose distributions with steep gradients are 
very well defined and the average difference with the 
expected dose from TPS was less than 1%. Moreover, the 
detector insensitivity on dose per pulse in conjunction with 
the low energy dependence typical of ionization chambers 
lead to high performances even when therapy beams feature 
extremely modulated dose rate and different qualities.  
